Marginal Zone Lymphoma Epidemiology Forecast

DelveInsight’s ‘Marginal Zone Lymphoma—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the MZL, historical and forecasted epidemiology as well as the MZL trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030


Marginal Zone Lymphoma Disease Understanding

Marginal zone B-cell lymphoma or Marginal Zone Lymphoma (MZL) is a group of indolent (slow-growing) NHL B-cell lymphomas, which account for approximately 5‒17% of all NHL cases. MZL account for about 5–10% of lymphomas and represent approximately 5–15% of all non-Hodgkin lymphomas in the Western world. They tend to be slow-growing (indolent). The cells in these lymphomas look small under the microscope. In the World Health Organization classification, there are three different MZL entities with specific diagnostic criteria, behavior, and therapeutic implications: the extranodal MZL of mucosa-associated lymphoid tissue (MALT) type (MALT lymphoma), the splenic MZL (SMZL), and the nodal MZL (NMZL). Currently, the first-line management of MZL totally depends on supportive therapies, and the two therapies that are approved are for relapsed and refractory MZL patient pool.


Marginal Zone Lymphoma Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total incident cases of Non-Hodgkin lymphoma, Total incident cases of Marginal Zone Lymphoma, Gender-specific incident cases of MZL, Subtype-specific incident cases of MZL, and Stage-specific incident cases of MZL, scenario of MZL in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.


Marginal Zone Lymphoma Detailed Epidemiology Segmentation

  • As per DelveInsight estimates, the incident cases of NHL in the 7MM was 166,967 cases in 2017.
  • The estimates suggest a higher incidence of MZL in the United States with 7,188 cases in 2017.
  • The epidemiological model of DelveInsight estimates a higher proportion of MZL cases was found in stage III as compared to other stages in the United States. In 2017, stage I, stage II, and stage III MZL incident cases were 1,416, 465, and 5,307 respectively, in the US.
  • MALT lymphoma has the highest incident population with 5,032 cases followed by SMZL with 1,438 cases and NMZL with 719 cases, in 2017, in the US.
  • Among the EU5 countries, the UK had the highest incident population of MZL with 3,142 cases, followed by France which had an incident population of 1,748 in 2017. On the other hand, Spain had the lowest incident population of 763 cases in 2017.


Scope of the Report

  • The report covers the descriptive overview of MZL, explaining its causes, symptoms, pathophysiology, and genetic basis.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of MZL.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total incident cases of Non-Hodgkin lymphoma, Total incident cases of Marginal Zone Lymphoma, Gender-specific incident cases of MZL, Subtype-specific incident cases of MZL, and Stage-specific incident cases of MZL.


Report Highlights

  • 11-Year Forecast of MZL
  • 7MM Coverage
  • Total incident cases of Non-Hodgkin lymphoma
  • Total incident cases of Marginal Zone Lymphoma
  • Gender-specific incident cases of MZL
  • Subtype-specific incident cases of MZL
  • Stage-specific incident cases of MZL.


Key Questions Answered

  • What are the disease risk, burden, and unmet needs of MZL?
  • What is the historical MZL patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of MZL at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to MZL?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of MZL during the forecast period (2020–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?


Reasons to buy

The MZL report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM MZL epidemiology forecast.
  • The MZL epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The MZL epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population


1 Key Insights

2 Executive Summary of Marginal Zone Lymphoma (MZL)

4 Disease Background and Overview: Marginal Zone Lymphoma (MZL)

4.1 Introduction

4.2 Role of infectious etiologies in the pathogenesis of MZLB-cell lymphomas

4.2.1 Association of chronic inflammation and infectious agents with MZL at various anatomical sites

4.2.2 The H. pylori and gastric MALT lymphoma pathogenetic model

4.2.3 C. psittaci and ocular adnexal MZL

4.2.4 B. burgdorferi in cutaneous MZL

4.2.5 Immunoproliferative small intestinal disease and C. jejuni

4.2.6 A. xyloxidans and pulmonary MALT lymphoma

4.2.7 Hepatitis C virus and MZLs

4.3 Biology of marginal zone lymphoma

4.3.1 NF-κB signaling

4.3.2 NOTCH signaling

4.3.3 KLF2

4.3.4 PTPRD

4.3.5 Chromatin remodeling and epigenome regulation

4.3.6 Antigen stimulation

4.4 Diagnosis of MZL

4.4.1 MALT

4.4.2 Nodal MZL

4.4.3 Splenic MZL

4.5 ESMO Clinical Practice Guidelines for diagnosis of MZL

4.5.1 Staging and risk assessment

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 KOL Views

6.3 Epidemiology Methodology

6.4 Total Incident Cases of Non-Hodgkin lymphoma (NHL) in the 7MM

6.5 Total Incident Cases of Marginal Zone Lymphoma (MZL) in the 7MM

7 United States Epidemiology

7.1 Assumptions and Rationale

7.1.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in the United States

7.1.2 Total incident cases of Marginal Zone Lymphoma (MZL) in the United States

7.1.3 Gender-specific incident cases of MZL in the United States

7.1.4 Subtype-specific incident cases of MZL in the United States

7.1.5 Stage-specific incident cases of MZL in the United States

8 EU5 Epidemiology

8.1 Assumptions and Rationale

8.2 Germany Epidemiology

8.2.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in Germany

8.2.2 Total incident cases of Marginal Zone Lymphoma (MZL) in Germany

8.2.3 Gender-specific incident cases of MZL in Germany

8.2.4 Subtype-specific incident cases of MZL in Germany

8.2.5 Stage-specific incident cases of MZL in Germany

8.3 France Epidemiology

8.3.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in France

8.3.2 Total incident cases of Marginal Zone Lymphoma (MZL) in France

8.3.3 Gender-specific incident cases of MZL in France

8.3.4 Subtype-specific incident cases of MZL in France

8.3.5 Stage-specific incident cases of MZL in France

8.4 Italy Epidemiology

8.4.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in Italy

8.4.2 Total incident cases of Marginal Zone Lymphoma (MZL) in Italy

8.4.3 Gender-specific incident cases of MZL in Italy

8.4.4 Subtype-specific incident cases of MZL in Italy

8.4.5 Stage-specific incident cases of MZL in Italy

8.5 Spain Epidemiology

8.5.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in Spain

8.5.2 Total incident cases of Marginal Zone Lymphoma (MZL) in Spain

8.5.3 Gender-specific incident cases of MZL in Spain

8.5.4 Subtype-specific incident cases of MZL in Spain

8.5.5 Stage-specific incident cases of MZL in Spain

8.6 United Kingdom Epidemiology

8.6.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in the United Kingdom

8.6.2 Total incident cases of Marginal Zone Lymphoma (MZL) in the UK

8.6.3 Gender-specific incident cases of MZL in the UK

8.6.4 Subtype-specific incident cases of MZL in the UK

8.6.5 Stage-specific incident cases of MZL in the UK

9 Japan Epidemiology

9.1 Assumptions and Rationale

9.1.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in Japan

9.1.2 Total incident cases of Marginal Zone Lymphoma (MZL) in Japan

9.1.3 Gender-specific incident cases of MZL in Japan

9.1.4 Subtype-specific incident cases of MZL in Japan

9.1.5 Stage-specific incident cases of MZL in Japan

10 Recognized Establishments

11 Appendix

11.1 Bibliography

11.2 Report Methodology

12 DelveInsight Capabilities

13 Disclaimer

14 About DelveInsight

List of Table

Table 1: Summary of Marginal Zone Lymphoma (MZL), Epidemiology and Key Events (2017–2030)

Table 2: Total Incident Cases of Non-Hodgkin lymphoma (NHL) in the 7MM (2017–2030)

Table 3: Total Incident Cases of Marginal Zone Lymphoma (MZL) in the 7MM (2017–2030)

Table 4: Major Sources Used

Table 5: Total incident cases of Non-Hodgkin lymphoma (NHL) in the United States (2017–2030)

Table 6: Total incident cases of Marginal Zone Lymphoma (MZL) in the United States (2017–2030)

Table 7: Gender-specific incident cases of MZL in the United States (2017–2030)

Table 8: Subtype-specific incident cases of MZL in the United States (2017–2030)

Table 9: Stage-specific incident cases of MZL in the United States (2017–2030)

Table 10: Total incident cases of Non-Hodgkin lymphoma (NHL) in Germany (2017–2030)

Table 11: Total incident cases of Marginal Zone Lymphoma (MZL) in Germany (2017–2030)

Table 12: Gender-specific incident cases of MZL in Germany (2017–2030)

Table 13: Subtype-specific incident cases of MZL in Germany (2017–2030)

Table 14: Stage-specific incident cases of MZL in Germany (2017–2030)

Table 15: Total incident cases of Non-Hodgkin lymphoma (NHL) in France (2017–2030)

Table 16: Total incident cases of Marginal Zone Lymphoma (MZL) in France (2017–2030)

Table 17: Gender-specific incident cases of MZL in France (2017–2030)

Table 18: Subtype-specific incident cases of MZL in France (2017–2030)

Table 19: Stage-specific incident cases of MZL in France (2017–2030)

Table 20: Total incident cases of Non-Hodgkin lymphoma (NHL) in Italy (2017–2030)

Table 21: Total incident cases of Marginal Zone Lymphoma (MZL) in Italy(2017–2030)

Table 22: Gender-specific incident cases of MZL in Italy (2017–2030)

Table 23: Type-specific incident cases of MZL in Italy (2017–2030)

Table 24: Stage-specific incident cases of MZL in Italy (2017–2030)

Table 25: Total incident cases of Non-Hodgkin lymphoma (NHL) in Spain (2017–2030)

Table 26: Total incident cases of Marginal Zone Lymphoma (MZL) in Spain (2017–2030)

Table 27: Gender-specific incident cases of MZL in Spain (2017–2030)

Table 28: Subtype-specific incident cases of MZL in Spain (2017–2030)

Table 29: Stage-specific incident cases of MZL in Spain (2017–2030)

Table 30: Total incident cases of Non-Hodgkin lymphoma (NHL) in the UK (2017–2030)

Table 31: Total incident cases of Marginal Zone Lymphoma (MZL) in the UK (2017–2030)

Table 32: Gender-specific incident cases of MZL in the UK (2017–2030)

Table 33: Subtype-specific incident cases of MZL in the UK (2017–2030)

Table 34: Stage-specific incident cases of MZL in the UK (2017–2030)

Table 35: Total incident cases of Non-Hodgkin lymphoma (NHL) in Japan (2017–2030)

Table 36: Total incident cases of Marginal Zone Lymphoma (MZL) in Japan(2017–2030)

Table 37: Gender-specific incident cases of MZL in Japan (2017–2030)

Table 38: Subtype-specific incident cases of MZL in Japan (2017–2030)

Table 39: Stage-specific incident cases of MZL in Japan (2017–2030)

List of Figures

Figure 1: H. pylori (HP)–induced lymphomagenesis

Figure 2: Summary of the main genetic and biologic features characterizing marginal zone lymphomas

Figure 3: Endoscopic Ultrasonography Staging of Gastric MALT Lymphoma

Figure 4: KOL Views

Figure 5: Total Incident Cases of Non-Hodgkin lymphoma (NHL) in the 7MM (2017–2030)

Figure 6: Total Incident Cases of Marginal Zone Lymphoma (MZL) in the 7MM (2017–2030)

Figure 7: Global Heat Map of NHL

Figure 8: Total incident cases of Non-Hodgkin lymphoma (NHL) in the United States (2017–2030)

Figure 9: Total incident cases of Marginal Zone Lymphoma (MZL) in the United States (2017–2030)

Figure 10: Gender-specific incident cases of MZL in the United States (2017–2030)

Figure 11: Subtype -specific incident cases of MZL in the United States (2017–2030)

Figure 12: Stage-specific incident cases of MZL in the United States (2017–2030)

Figure 13: Total incident cases of Non-Hodgkin lymphoma (NHL) in Germany (2017–2030)

Figure 14: Total incident cases of Marginal Zone Lymphoma (MZL) in Germany (2017–2030)

Figure 15: Gender-specific incident cases of MZL in Germany (2017–2030)

Figure 16: Subtype-specific incident cases of MZL in Germany (2017–2030)

Figure 17: Stage-specific incident cases of MZL in Germany (2017–2030)

Figure 18: Total incident cases of Non-Hodgkin lymphoma (NHL) in France (2017–2030)

Figure 19: Total incident cases of Marginal Zone Lymphoma (MZL) in France (2017–2030)

Figure 20: Gender-specific incident cases of MZL in France (2017–2030)

Figure 21: Subtype-specific incident cases of MZL in France (2017–2030)

Figure 22: Stage-specific incident cases of MZL in France (2017–2030)

Figure 23: Total incident cases of Non-Hodgkin lymphoma (NHL) in Italy (2017–2030)

Figure 24: Total incident cases of Marginal Zone Lymphoma (MZL) in Italy (2017–2030)

Figure 25: Gender-specific incident cases of MZL in Italy (2017–2030)

Figure 26: Subtype-specific incident cases of MZL in Italy (2017–2030)

Figure 27: Stage-specific incident cases of MZL in Italy (2017–2030)

Figure 28: Total incident cases of Non-Hodgkin lymphoma (NHL) in Spain (2017–2030)

Figure 29: Total incident cases of Marginal Zone Lymphoma (MZL) in Spain (2017–2030)

Figure 30: Gender-specific incident cases of MZL in Spain (2017–2030)

Figure 31: Subtype-specific incident cases of MZL in Spain (2017–2030)

Figure 32: Stage-specific incident cases of MZL in Spain (2017–2030)

Figure 33: Total incident cases of Non-Hodgkin lymphoma (NHL) in the UK (2017–2030)

Figure 34: Total incident cases of Marginal Zone Lymphoma (MZL) in the UK (2017–2030)

Figure 35: Gender-specific incident cases of MZL in the UK (2017–2030)

Figure 36: Subtype-specific incident cases of MZL in the UK (2017–2030)

Figure 37: Stage-specific incident cases of MZL in the UK (2017–2030)

Figure 38: Total incident cases of Non-Hodgkin lymphoma (NHL) in Japan (2017–2030)

Figure 39: Total incident cases of Marginal Zone Lymphoma (MZL) in Japan (2017–2030)

Figure 40: Gender-specific incident cases of MZL in Japan (2017–2030)

Figure 41: Subtype-specific incident cases of MZL in Japan (2017–2030)

Figure 42: Stage-specific incident cases of MZL in Japan (2017–2030)

  • Tags:
  • Marginal Zone Lymphoma Epidemiology
  • Marginal Zone Lymphoma
  • Marginal Zone Lymphoma Pipeline
  • Marginal Zone Lymphoma Companies
  • Marginal Zone Lymphoma prevalent p...
  • Marginal Zone Lymphoma incident po...
  • Marginal Zone Lymphoma patients di...
  • Marginal Zone Lymphoma treatment a...

Forward to Friend

Need A Quote